Nijmegen, the Netherlands – Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, has announced a distribution collaboration with Paige, a global leader in AI-based diagnostic software in pathology. This partnership will allow pathology laboratories to seamlessly access and incorporate Aiosyn’s automated quality control (QC) solution into their workflow via the Paige AppLabTM.
“Aiosyn’s strategy is to deploy pathology algorithms using a vendor-neutral and modular approach. Paige has proven to be one of the standard digital pathology platforms, and their AppLab solution enables us to deploy and scale our AI solutions worldwide.”
Patrick de Boer, CEO of Aiosyn
“We are excited to start this partnership with our quality control algorithm, which automates the detection of artifacts on whole slide images and can boost the efficiency and reduce the turnaround time of pathology examinations.”, Patrick continued.
AiosynQC identifies and flags the most common artifacts in digital histology slides (e.g., out-of-focus areas, air bubbles), helping pathology labs to ensure that only high-quality images are sent for further review and reducing time spent on manual quality checks. The algorithm is compatible with hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining and offers customization options to adjust sensitivity thresholds and reporting according to user requirements.
The Paige Platform is a comprehensive digital pathology software platform with viewer and storage capabilities. It is compatible with existing digital pathology solutions, including most scanners, monitors, and laboratory information systems (LIS). The integration of AiosynQC into Paige’s AppLab provides laboratories using the software with an efficient pre-analytical tool that can reduce the turnaround time of pathology slides.
“Paige is dedicated to empowering pathologists with premier tools designed for real-world clinical utilization and we are thrilled to have Aiosysn join us in that commitment. The addition of AisoynQC to the Paige AppLab provides a simple and seamless solution for pathologists to integrate AI-powered quality control into their workflows which can further enhance the efficiency that digital pathology brings.” said Andy Moye, CEO of Paige.
Following the integration of AiosynQC into the Sectra Amplifier Marketplace in May last year, its availability on the Paige AppLab represents another significant milestone for Aiosyn in its mission to provide AI-powered pathology anywhere, anytime. Aiosyn is dedicated to expanding its portfolio of deep learning algorithms, currently under development for breast cancer and kidney diseases, and integrating them into standard platforms, including Paige’s AppLab.
Aiosyn is a Dutch company that develops precision pathology software for cancer and kidney disease. Aiosyn’s solutions are integrated into standard pathology workflows. The Aiosyn team has been built upon more than 20 years of research experience in the field of pathology and is rooted into the pathology practice.
Paige uses the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment.